Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated single-concentration SCIT after SLIT discontinuation in children and adolescents with dust mite allergic rhinitis
ChiCTR2600131057Phase 4Not yet recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of alutard-sq and Novo-Helisen Depot in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma (2 arms), sponsored by Hunan Provincial People's Hospital. Primary endpoint: Median time to achieve a 30% reduction in VAS score from baseline. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
alutard-sqNovo-Helisen Depot
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on ChiCTR2600131057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131057.